WO2009051108A1 - 抗体の製造方法 - Google Patents

抗体の製造方法 Download PDF

Info

Publication number
WO2009051108A1
WO2009051108A1 PCT/JP2008/068588 JP2008068588W WO2009051108A1 WO 2009051108 A1 WO2009051108 A1 WO 2009051108A1 JP 2008068588 W JP2008068588 W JP 2008068588W WO 2009051108 A1 WO2009051108 A1 WO 2009051108A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fragment
chain
dna encoding
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/068588
Other languages
English (en)
French (fr)
Inventor
Yoshiki Yamada
Tatsuya Kiyasu
Kazuyuki Tabata
Akihiro Kuzumaki
Mai Yamashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009051108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL08838661T priority Critical patent/PL2202307T5/pl
Priority to BRPI0818674-0A priority patent/BRPI0818674B1/pt
Priority to CN200880106430A priority patent/CN101802192A/zh
Priority to MX2010004007A priority patent/MX2010004007A/es
Priority to DK08838661.0T priority patent/DK2202307T4/da
Priority to US12/734,094 priority patent/US9683027B2/en
Priority to AU2008312937A priority patent/AU2008312937B2/en
Priority to ES08838661T priority patent/ES2499391T5/es
Priority to EP08838661.0A priority patent/EP2202307B2/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to CA2701338A priority patent/CA2701338C/en
Priority to SI200831306T priority patent/SI2202307T2/sl
Priority to JP2009538093A priority patent/JP4976502B2/ja
Publication of WO2009051108A1 publication Critical patent/WO2009051108A1/ja
Priority to IL205051A priority patent/IL205051A/en
Anticipated expiration legal-status Critical
Priority to AU2015202051A priority patent/AU2015202051B2/en
Priority to IL240122A priority patent/IL240122B/en
Priority to US15/589,000 priority patent/US11136375B2/en
Priority to US17/233,008 priority patent/US12145978B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

　効率よく安価に組換え抗体を生産することができる方法を提供する。 　抗体のL鎖又はその断片をコードする外来DNAを抗体のH鎖又はその断片をコードする外来DNAよりも多いコピー数で含む細胞を用いて抗体又はその断片を産生させることを含む、抗体又はその断片の製造方法。抗体のH鎖又はその断片をコードするDNAを1コピー、L鎖又はその断片をコードするDNAを2コピー以上含む組換えベクター及び形質転換細胞なども提供される。
PCT/JP2008/068588 2007-10-15 2008-10-14 抗体の製造方法 Ceased WO2009051108A1 (ja)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SI200831306T SI2202307T2 (sl) 2007-10-15 2008-10-14 Postopek za proizvodnjo protitelesa
CA2701338A CA2701338C (en) 2007-10-15 2008-10-14 Method for production of antibody
CN200880106430A CN101802192A (zh) 2007-10-15 2008-10-14 抗体的制备方法
MX2010004007A MX2010004007A (es) 2007-10-15 2008-10-14 Metodo para la produccion de un anticuerpo.
DK08838661.0T DK2202307T4 (da) 2007-10-15 2008-10-14 Fremgangsmåde til fremstiling af et antistof
US12/734,094 US9683027B2 (en) 2007-10-15 2008-10-14 Method for production of antibody
AU2008312937A AU2008312937B2 (en) 2007-10-15 2008-10-14 Method for production of antibody
ES08838661T ES2499391T5 (es) 2007-10-15 2008-10-14 Método para la producción de anticuerpos
EP08838661.0A EP2202307B2 (en) 2007-10-15 2008-10-14 Method for production of antibody
PL08838661T PL2202307T5 (pl) 2007-10-15 2008-10-14 Sposób wytwarzania przeciwciała
JP2009538093A JP4976502B2 (ja) 2007-10-15 2008-10-14 抗体の製造方法
BRPI0818674-0A BRPI0818674B1 (pt) 2007-10-15 2008-10-14 Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
IL205051A IL205051A (en) 2007-10-15 2010-04-13 Method for producing antibodies
AU2015202051A AU2015202051B2 (en) 2007-10-15 2015-04-22 Method for production of antibody
IL240122A IL240122B (en) 2007-10-15 2015-07-23 A method for producing an antibody
US15/589,000 US11136375B2 (en) 2007-10-15 2017-05-08 Method for production of antibody
US17/233,008 US12145978B2 (en) 2007-10-15 2021-04-16 Composition comprising an antibody

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-267384 2007-10-15
JP2007267384 2007-10-15
JP2008103308 2008-04-11
JP2008-103308 2008-04-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/734,094 A-371-Of-International US9683027B2 (en) 2007-10-15 2008-10-14 Method for production of antibody
US15/589,000 Division US11136375B2 (en) 2007-10-15 2017-05-08 Method for production of antibody

Publications (1)

Publication Number Publication Date
WO2009051108A1 true WO2009051108A1 (ja) 2009-04-23

Family

ID=40567372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068588 Ceased WO2009051108A1 (ja) 2007-10-15 2008-10-14 抗体の製造方法

Country Status (17)

Country Link
US (3) US9683027B2 (ja)
EP (1) EP2202307B2 (ja)
JP (4) JP4976502B2 (ja)
KR (1) KR101558009B1 (ja)
CN (3) CN103540632A (ja)
AU (1) AU2008312937B2 (ja)
BR (1) BRPI0818674B1 (ja)
CA (1) CA2701338C (ja)
DK (1) DK2202307T4 (ja)
ES (1) ES2499391T5 (ja)
IL (2) IL205051A (ja)
MX (1) MX2010004007A (ja)
PL (1) PL2202307T5 (ja)
SG (1) SG185302A1 (ja)
SI (1) SI2202307T2 (ja)
TW (1) TWI463010B (ja)
WO (1) WO2009051108A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
WO2025135144A1 (ja) 2023-12-22 2025-06-26 中外製薬株式会社 抗体の製造方法
WO2025143225A1 (ja) 2023-12-27 2025-07-03 中外製薬株式会社 抗体の製造方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2202307T5 (pl) 2007-10-15 2021-10-04 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania przeciwciała
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
CA2903589A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
JP6563910B2 (ja) 2013-07-04 2019-08-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992019759A1 (fr) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2006006693A1 (ja) * 2004-07-09 2006-01-19 Chugai Seiyaku Kabushiki Kaisha 抗グリピカン３抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090969C (en) † 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5531053A (en) 1994-06-14 1996-07-02 Hamm; Hans Spring fastener for holding insulation against an inner surface of cavity walling
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
EP0985033A4 (en) * 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1383800A4 (en) † 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
US6605176B2 (en) 2001-07-13 2003-08-12 Taiwan Semiconductor Manufacturing Co., Ltd. Aperture for linear control of vacuum chamber pressure
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
ATE420964T1 (de) 2001-11-16 2009-01-15 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
EP2204190A1 (en) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
EP1733034A4 (en) * 2004-03-15 2010-01-20 Biogen Idec Inc METHOD AND CONSTRUCTS FOR THE EXPRESSION OF POLYPEPTIDE MULTIMERS IN EUKARYONTIC CELLS USING ALTERNATIVE SPLEISSEN
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
CN101595228A (zh) * 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
PL2202307T5 (pl) * 2007-10-15 2021-10-04 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania przeciwciała

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992019759A1 (fr) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2006006693A1 (ja) * 2004-07-09 2006-01-19 Chugai Seiyaku Kabushiki Kaisha 抗グリピカン３抗体

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS
BIOTECHNOL. PROG., vol. 21, 2005, pages 122
CARL, A. K. BORREBAECK; JAMES, W. LARRICK: "United Kingdom", 1990, MACMILLAN PUBLISHERS LTD, article "THERAPEUTIC MONOCLONAL ANTIBODIES"
CHO, J. EXP. MED., vol. 108, 1995, pages 945
DORAI H. ET AL.: "Correlation of heavy and light chain mRNA copy numbers to antibody productivity in mouse myeloma production cell lines.", HYBRIDOMA, vol. 25, 2006, pages 1 - 9, XP008116842 *
EBERT ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702
JIANG Z. ET AL.: "Regulation of recombinant monoclonal antibody production in chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression.", BIOTECHNOL. PROG., vol. 22, 2006, pages 313 - 318, XP002525683 *
JULIAN ET AL., EUR. J: IMMUNOL., vol. 24, 1994, pages 131 - 138
KOHLER, G; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KOLB A.F. ET AL.: "A virus-neutralising antibody is not cytotoxic in vitro.", MOL. IMMUNOL., vol. 43, 2006, pages 677 - 689, XP025037174 *
LEE YK. ET AL.: "BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly.", MOL. BIOL. CELL, vol. 10, 1999, pages 2209 - 2219, XP008123368 *
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
MOLECULAR BIOLOGY OF THE CELL, vol. 10, 1999, pages 2209
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
NIWA ET AL., GENE, vol. 108, 1991, pages 193
PRESTA LG; CHEN H; O'CONNOR SJ; CHISHOLM V; MENG YQ; KRUMMEN L ET AL.: "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders", CANCER RES., vol. 57, no. 20, 15 October 1997 (1997-10-15), pages 4593 - 9
PROC. NATL. ACAD. SCI. USA, vol. 60, 1968, pages 1275
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 7380 - 7384
REFF ME; CARNER K; CHAMBERS KS; CHINN PC; LEONARD JE; RAAB R ET AL.: "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", BLOOD, vol. 83, no. 2, 15 January 1994 (1994-01-15), pages 435 - 45
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
SCHLATTER S. ET AL.: "On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells", BIOTECHNOL. PROG., vol. 21, 2005, pages 122 - 133, XP008123445 *
See also references of EP2202307A1
SUSUMU ET AL., NATURE, vol. 315, 1985, pages 592 - 594
VAIIE ET AL., NATURE, vol. 291, 1981, pages 358 - 340
VICKI GLASER, SPECTRUM BIOTECHNOLOGY APPLICATIONS, 1993

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
WO2025135144A1 (ja) 2023-12-22 2025-06-26 中外製薬株式会社 抗体の製造方法
WO2025134341A1 (ja) * 2023-12-22 2025-06-26 中外製薬株式会社 抗体の製造方法
WO2025143225A1 (ja) 2023-12-27 2025-07-03 中外製薬株式会社 抗体の製造方法

Also Published As

Publication number Publication date
DK2202307T4 (da) 2021-10-04
PL2202307T5 (pl) 2021-10-04
JP5788830B2 (ja) 2015-10-07
EP2202307A4 (en) 2012-01-25
TW200934867A (en) 2009-08-16
CN101802192A (zh) 2010-08-11
JP6092304B2 (ja) 2017-03-08
SI2202307T2 (sl) 2021-11-30
BRPI0818674A2 (pt) 2014-10-14
JP2012143246A (ja) 2012-08-02
IL240122A0 (en) 2015-09-24
KR20100074184A (ko) 2010-07-01
SI2202307T1 (sl) 2014-11-28
US9683027B2 (en) 2017-06-20
JP4976502B2 (ja) 2012-07-18
CA2701338A1 (en) 2009-04-23
DK2202307T3 (da) 2014-09-15
US20210300996A1 (en) 2021-09-30
CA2701338C (en) 2018-09-18
ES2499391T3 (es) 2014-09-29
BRPI0818674B1 (pt) 2023-01-17
TWI463010B (zh) 2014-12-01
JP2015198663A (ja) 2015-11-12
IL205051A (en) 2015-09-24
MX2010004007A (es) 2010-06-15
AU2008312937B2 (en) 2015-01-22
JPWO2009051108A1 (ja) 2011-03-03
PL2202307T3 (pl) 2015-02-27
JP6506786B2 (ja) 2019-04-24
KR101558009B1 (ko) 2015-10-19
US20170275351A1 (en) 2017-09-28
EP2202307A1 (en) 2010-06-30
EP2202307B2 (en) 2021-07-14
AU2008312937A1 (en) 2009-04-23
IL205051A0 (en) 2010-11-30
US20100291627A1 (en) 2010-11-18
CN106244651A (zh) 2016-12-21
IL240122B (en) 2019-02-28
EP2202307B1 (en) 2014-08-20
US11136375B2 (en) 2021-10-05
US12145978B2 (en) 2024-11-19
SG185302A1 (en) 2012-11-29
JP2017079794A (ja) 2017-05-18
ES2499391T5 (es) 2021-12-22
CN103540632A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
MX2010004007A (es) Metodo para la produccion de un anticuerpo.
AU2018200640B2 (en) Humanization of rabbit antibodies using a universal antibody framework
SG170837A1 (en) Antibody purification
WO2010046775A3 (en) Methods for producing antibodies from plasma cells
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
WO2008033517A3 (en) Cell culture improvements
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
BRPI0813242A2 (pt) Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
BRPI0908450A2 (pt) Vetor para transformação usando transposons, micro-organismos transformados pelo vetor e método para produzir l-lisina usando o mesmo
BRPI0808104A2 (pt) Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante
WO2008003116A3 (en) Method for engineering immunoglobulins
EP4328304A3 (en) Engineered cleavage half-domains
WO2008045199A3 (en) Method and system for allowing access to developed applications via a multi-tenant on-demand database service
MY172718A (en) Humanized universal light chain mice
EP4026901A3 (en) Method for screening alpha-amylases
ATE513907T1 (de) Polypeptide mit endoglucanase-aktivität und polynukleotide zu ihrer kodierung
WO2008084535A1 (ja) ケーブル曲線生成システム、方法、及びプログラム
AR084234A1 (es) Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
WO2008143708A3 (en) Methods and materials related to anti-amyloid antibodies
WO2010088411A3 (en) Conformationally dynamic peptides
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
DK2431470T3 (da) DNase expression i rekombinante værtsceller
BRPI0813913A2 (pt) Molécula de ácido nucleico, sequência de ácido nucleico recombinante, célula hospedeira, métodos para produzir fsh humano recombinante, e para produzir a célula hospedeira, e, uso de uma sequência de ácido nucleico.
BRPI1013484A2 (pt) "protease, dna, vetor de expressão , célula transformada, e, método para produzir uma protease".

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880106430.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08838661

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009538093

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2701338

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12734094

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2041/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 205051

Country of ref document: IL

Ref document number: MX/A/2010/004007

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20107008087

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008838661

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008312937

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008312937

Country of ref document: AU

Date of ref document: 20081014

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0818674

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100415

WWE Wipo information: entry into national phase

Ref document number: 240122

Country of ref document: IL